SG10201810575WA - Treatment of prostate cancer with tor kinase inhibitors - Google Patents
Treatment of prostate cancer with tor kinase inhibitorsInfo
- Publication number
- SG10201810575WA SG10201810575WA SG10201810575WA SG10201810575WA SG10201810575WA SG 10201810575W A SG10201810575W A SG 10201810575WA SG 10201810575W A SG10201810575W A SG 10201810575WA SG 10201810575W A SG10201810575W A SG 10201810575WA SG 10201810575W A SG10201810575W A SG 10201810575WA
- Authority
- SG
- Singapore
- Prior art keywords
- prostate cancer
- tor kinase
- treatment
- kinase inhibitors
- tor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
Abstract
TREATMENT OF PROSTATE CANCER WITH TOR KINASE INHIBITORS Provided herein are methods for treating or preventing prostate cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having prostate cancer. [Figure Number 1]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261715510P | 2012-10-18 | 2012-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201810575WA true SG10201810575WA (en) | 2019-01-30 |
Family
ID=50023830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201810575WA SG10201810575WA (en) | 2012-10-18 | 2013-10-17 | Treatment of prostate cancer with tor kinase inhibitors |
| SG11201502999YA SG11201502999YA (en) | 2012-10-18 | 2013-10-17 | Treatment of prostate cancer with tor kinase inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502999YA SG11201502999YA (en) | 2012-10-18 | 2013-10-17 | Treatment of prostate cancer with tor kinase inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140113904A1 (en) |
| EP (1) | EP2908814B1 (en) |
| JP (3) | JP2015534981A (en) |
| KR (2) | KR102267927B1 (en) |
| CN (2) | CN110721186A (en) |
| AU (1) | AU2013202768B2 (en) |
| BR (1) | BR112015008834A2 (en) |
| CA (1) | CA2888609C (en) |
| EA (1) | EA029164B1 (en) |
| ES (1) | ES2777936T3 (en) |
| IL (1) | IL238326B (en) |
| MX (1) | MX368407B (en) |
| MY (1) | MY176599A (en) |
| NI (1) | NI201500055A (en) |
| PH (1) | PH12015500867B1 (en) |
| SG (2) | SG10201810575WA (en) |
| UA (1) | UA117000C2 (en) |
| WO (1) | WO2014062878A2 (en) |
| ZA (1) | ZA201503105B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| AR094494A1 (en) | 2013-01-16 | 2015-08-05 | Signal Pharm Llc | REPLACED PIRROLOPIRIMIDINS, THEIR COMPOSITIONS, AND THEIR TREATMENT METHODS |
| JP2017514806A (en) | 2014-04-16 | 2017-06-08 | シグナル ファーマシューティカルズ，エルエルシー | Methods of treating cancer using TOR kinase inhibitor combination therapy |
| JP2017520603A (en) | 2014-07-14 | 2017-07-27 | シグナル ファーマシューティカルズ，エルエルシー | Method for treating cancer using substituted pyrrolopyrimidine compound and composition thereof |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| WO2017087837A1 (en) * | 2015-11-20 | 2017-05-26 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| BR112019027402A2 (en) | 2017-06-22 | 2020-07-07 | Celgene Corporation | treatment of hepatocellular carcinoma characterized by infection with the hepatitis b virus |
| CN110403943B (en) * | 2019-08-19 | 2022-05-17 | 陕西科技大学 | Application of CC-115 in preparation of antifungal drugs and pharmaceutical composition thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1159582C (en) * | 2001-12-08 | 2004-07-28 | 云南大学 | Method for detecting total PSA value and total PSA gray zone value in whole blood or serum of human body and test paper for carcinoma of prostate |
| GB0509748D0 (en) | 2005-05-13 | 2005-06-22 | Univ Glasgow | Materials and methods relating to cell based therapies |
| US20070238745A1 (en) * | 2006-04-07 | 2007-10-11 | University Of South Florida | PI3K-Akt Pathway Inhibitors |
| EP2457913B1 (en) * | 2006-10-19 | 2017-04-19 | Signal Pharmaceuticals, LLC | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| EP2078018B1 (en) | 2006-10-19 | 2012-03-14 | Signal Pharmaceuticals LLC | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| EP2349984A1 (en) * | 2008-10-17 | 2011-08-03 | Merck & Co. | Combination therapy |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| NZ599549A (en) * | 2009-10-26 | 2013-11-29 | Signal Pharm Llc | Methods of synthesis and purification of heteroaryl compounds |
| US20120238562A1 (en) * | 2011-03-09 | 2012-09-20 | Cedars-Sinai Medical Center | Treatment of cancer by targeting molecules that influence mst1/stk4 signaling |
-
2013
- 2013-04-06 AU AU2013202768A patent/AU2013202768B2/en active Active
- 2013-10-17 KR KR1020207026267A patent/KR102267927B1/en active IP Right Grant
- 2013-10-17 MY MYPI2015701232A patent/MY176599A/en unknown
- 2013-10-17 KR KR1020157012636A patent/KR102157914B1/en active IP Right Grant
- 2013-10-17 BR BR112015008834A patent/BR112015008834A2/en not_active Application Discontinuation
- 2013-10-17 MX MX2015004874A patent/MX368407B/en active IP Right Grant
- 2013-10-17 CN CN201910935268.7A patent/CN110721186A/en active Pending
- 2013-10-17 EP EP13824539.4A patent/EP2908814B1/en active Active
- 2013-10-17 EA EA201590744A patent/EA029164B1/en not_active IP Right Cessation
- 2013-10-17 SG SG10201810575WA patent/SG10201810575WA/en unknown
- 2013-10-17 US US14/055,985 patent/US20140113904A1/en not_active Abandoned
- 2013-10-17 ES ES13824539T patent/ES2777936T3/en active Active
- 2013-10-17 CN CN201380066349.9A patent/CN105050601A/en active Pending
- 2013-10-17 SG SG11201502999YA patent/SG11201502999YA/en unknown
- 2013-10-17 WO PCT/US2013/065363 patent/WO2014062878A2/en active Application Filing
- 2013-10-17 CA CA2888609A patent/CA2888609C/en active Active
- 2013-10-17 JP JP2015537809A patent/JP2015534981A/en active Pending
- 2013-10-17 UA UAA201504749A patent/UA117000C2/en unknown
-
2015
- 2015-04-16 IL IL238326A patent/IL238326B/en active IP Right Grant
- 2015-04-17 NI NI201500055A patent/NI201500055A/en unknown
- 2015-04-17 PH PH12015500867A patent/PH12015500867B1/en unknown
- 2015-05-06 ZA ZA2015/03105A patent/ZA201503105B/en unknown
-
2019
- 2019-01-28 JP JP2019012014A patent/JP7162543B2/en active Active
-
2020
- 2020-11-30 JP JP2020199055A patent/JP2021050213A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502234B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| MX357833B (en) | Treatment of cancer with tor kinase inhibitors. | |
| PH12014502047A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| PH12017501500A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
| PH12014502029A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| MX2015014596A (en) | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer. | |
| SG10201810575WA (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| CA2909625C (en) | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer | |
| PH12014502046B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| MX2015014599A (en) | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer. | |
| TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor |